Skip to content

Canadian incremental dialysis to improve health outcomes in people starting hemodialysis

CANadian INCremental dialysis to improve Health outcomes in people starting Hemodialysis (CAN INCH-HD) study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN78497421
Enrollment
150
Registered
2023-07-15
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult patients with end stage kidney disease requiring hemodialysis Digestive System Chronic kidney disease, stage 5

Interventions

Experimental Arm Incremental HD: Participants will initiate HD at a frequency of 2x/week and continue until an indication for an increase to 3x/week (trigger point) is reached. Trigger points include

Sponsors

Canadian Institutes of Health Research
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adults (=18 years old) starting HD as their initial dialysis therapy 2. Able to give informed consent

Exclusion criteria

Exclusion criteria: 1. Urine output <0.5 l/day 2. Unlikely to be on dialysis for =1 year Since RKF and QOL at 18 months are secondary outcomes, adequate urine output at HD start and likelihood of needing chronic maintenance HD long-term are required.

Design outcomes

Primary

MeasureTime frame
Quality of life (QOL) assessed by the Kidney Disease Quality of Life Short Form (KDQOL-SF 1.3) at 6 months after HD start

Secondary

MeasureTime frame
1. Residual kidney function (RKF) (difference in mean of 24-hour urinary urea and creatinine clearances between groups) at baseline, months 3, 6, 12 and 18 2. Anuria: the proportion of patients with anuria (<200 ml urine output/24 h) and time to anuria at baseline, months 3, 6, 12 and 18 3. Safety (time to all-cause mortality; time to first major cardiovascular event [MACE]; number of non-elective hospital admissions and total hospital days; time to death and hospital admissions, episodes of hyperkalemia [=6.5 mmol/L]; extra HD sessions for fluid overload; vascular access procedures [SONG-HD core outcome]) assessed at monthly visits for 18 months 4. Quality of life measured using monthly EQ-5D-5L and quarterly KDQOL-SF 1.3 (all components) at baseline and monthly for 18 months 5. Symptom scores assessed by KDQOL-SF 1.3 (physical component and mental component summaries) at baseline, months 3, 6, 9, 12, 15, 18 6. Fatigue assessed by SONG-HD core outcome measure at baseline, months 3, 6, 9, 12, 15 and 18 7. Nutritional status assessed by Subjective Global Assessment (SGA) at baseline, months 3, 6, 12 and 18 8. Cost analysis recorded by participants in the Health Care Diary collected at baseline and monthly for 18 months

Countries

Australia, Canada, New Zealand

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026